Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Radical sinus surgery may beat standard for tough nasal polyps

NCT ID NCT04852562

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compared two types of sinus surgery for people with chronic sinusitis and nasal polyps that involve a type of inflammation called eosinophilic. One surgery (MRESS) removes more tissue, including the middle turbinate, while the standard surgery (FESS) preserves it. The goal was to see if the more radical approach improves quality of life and reduces the need for repeat surgery. 110 Chinese patients were followed for a year after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
modified radical endoscopic sinus surgery (MRESS)
What this could lead to
If MRESS proves better, it could offer a more effective surgical option for people with stubborn nasal polyps, reducing symptoms and the need for repeat surgery.
What could go wrong
This is a small, single-center study (110 patients) with no blinding. Results may not apply to all patients, and more radical surgery carries higher risks like bleeding or scarring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

110 people

The number who actually took part.

Started

Dec 2020

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CRSwNP is diagnosed according to EPOS clinical guidelines and met surgical requirements, the blood eosinophil count was greater than 0.22; * Subjects/legal authorized representatives must understand the purpose and procedures of the study and voluntarily sign the informed consent, voluntarily participate in the study and comply with the study regulations, understand and comply with follow-up plan, and can correctly record the scale score, the administration frequency, accompanying drug use and adverse events, etc; * The examinee must be 18-65 years old, male or non pregnant female, limited to Chinese; * During the treatment and follow-up period, female subjects have no pregnancy and lactation plans; * The subjects did not participate in other clinical trials in the past three months and agreed not to participate in other clinical trials before reaching the end point of this trial; * Patients accompanying asthma must use their regular asthma treatment steadily in the past 6 weeks; Exclusion Criteria: * Women must not be pregnant, or breast-feeding; * Subjects with cystic fibrosis, congenital ciliary dyskinesia, fungal sinusitis, systemic vasculitis and granulomatous disease, tumor, and immunodeficiency are exclued; * Subjects accpted nasal endoscopic surgery within 6 months are exclued; * Subjects with an upper respiratory tract infection within 4 weeks of entering the study are excluded; * Subjects with serious metabolic, cardiovascular, autoimmune, neurology, blood, digestive, cerebrovascular, or respiratory system disease, or any disease interfering with the evaluation of results or affecting subjects safety are excluded, such as glaucoma and tuberculosis; * Currently participating in other clinical studies or in other clinical investigators within 30 days, or staff directly involved in this study; * Subjects with emotional or mental problems are excluded; * Subjects must not have received immunotherapy within the previous 3 months; * Subjects unsuitable for inclusion based on judgement of researchers are excluded;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic sinusitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of ENT, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.